FIGURE 1


Total Number Patients Enrolled and Treated as of Data Cutoff Dates
(29 April 2016 for non-UC; 24 July 2016 for UC)
N = 1022
As-treated Population
Initiated therapy ≥ 30 days prior to data cutoff dates
N = 1012
Total 10 mg/kg Q2W Population
N = 970*
N = 6
Dose Escalation/Exploration Population
N = 48
Non-UC
N=779
UC
N=191
Primary Efficacy Population
Initiated therapy ≥ 13 weeks prior to data cutoff date
N=103
2L+ Post Platinum
N = 94
Treatment naive/1L
N = 9
Cisplatin ineligible
N = 7
Cisplatin eligible
N = 2
*The total 10 mg/kg Q2W population included 6 subjects
from the 10mg/kg Q2W cohort in the dose-escalation phase.

FIGURE 2


Probability of Remaining in Response
1.0
0.8
0.6
0.4
0.2
0.0
Time (months)
0
3
6
9
12
15
18
21
# of Subjects at Risk
21 18 16 7 1 1 1 1
All
# of Subjects (# of Events) 21 (3)
Median (months) (95% CI) NR (NE, NE)
Prob. Remaining in Resp at 6 months (95% CI) 100% (NE, NE)
Prob. Remaining in Resp at 9 months (95% CI) 81% (52, 94%)

FIGURE 3


Off treatment
Time to response
Response ongoing
0
3
6
9
12
15
18
21
24
Months Since Treatment Initiation
PD-L1 High
PD-L1 Low/Neg

FIGURE 4


(a) High
(b) Low/Neg
(c) All
# of Subjects (# of Events) 61 (19) 39 (20) 103(39)
Median (months) (95% CI) NR (7.7, NE) 3.3(2.4, 14.1) 14.1 (4.5, NE)
OS - 6 months (95% CI) 68% (54, 79%) 45% (27, 61%) 60% (49, 70%)
OS - 9 months (95% CI) 65% (50, 77%) 36% (16, 56%) 56% (43, 66%)
OS -12 months (95% CI) 60% (43, 74%) 36% (16, 56%) 52% (39, 64%)
OS Rate
1.0
0.8
0.6
0.4
0.2
0.0
(a)
(b)
(c)
Time (months)
0 3 6 9 12 15 18 21 24
# of Subjects at Risk
(a) 61 36 23 19 13 4 3 2
(b) 39 16 5 4 3 1 1
(c) 103 55 28 23 16 5 4 2